| Literature DB >> 28286261 |
Shinya Neri1, Tomoyuki Miyashita2, Hiroko Hashimoto3, Yoshitaka Suda2, Masayuki Ishibashi3, Hiroaki Kii4, Hirotada Watanabe4, Takeshi Kuwata3, Masahiro Tsuboi5, Koichi Goto6, Toshi Menju7, Makoto Sonobe7, Hiroshi Date7, Atsushi Ochiai2, Genichiro Ishii8.
Abstract
Cancer-associated fibroblast (CAF)-dependent local invasion is the process by which cancer cells invade the extracellular matrix using tracks that have been physically remodeled by CAFs. In the present study, we investigated the process by which the epithelial-mesenchymal transition (EMT) of cancer cells affect CAF-dependent local invasion. Using an in vitro collagen invasion assay, we showed cancer cells undergoing EMT to promote the matrix-remodeling ability of CAFs and thereby enhance CAF-dependent local cancer cell invasion. Platelet-derived growth factor (PDGF)-BB secretion was significantly elevated in cancer cells undergoing EMT, and this induced an increase in the invasion ability of both CAFs and cancer cells. Conversely, knockdown of PDGF-B expression in cancer cells undergoing EMT, or treatment with a PDGF-receptor inhibitor, decreased the invasion ability of both CAFs and cancer cells. By analyzing the gene expression profiles of 442 patients with lung adenocarcinomas, we established that high expression of PDGF-B and presentation of mesenchymal-like tumors were significantly associated with a high rate of disease recurrence and poor patient prognosis. Thus, cancer cells undergoing EMT may accelerate their own ability to invade local tissues via PDGF-BB secretion to promote CAF matrix remodeling. Therefore, targeting PDGF signaling between cancer cells undergoing EMT and CAFs is a promising therapeutic target to inhibit cancer progression and improve patient prognosis.Entities:
Keywords: Cancer-associated fibroblasts; Epithelial–mesenchymal transition; Extracellular matrix remodeling; Fibroblast-dependent cancer invasion; Platelet-derived growth factor B
Mesh:
Substances:
Year: 2017 PMID: 28286261 DOI: 10.1016/j.canlet.2017.02.026
Source DB: PubMed Journal: Cancer Lett ISSN: 0304-3835 Impact factor: 8.679